Bath Savings Trust Co Decreases Position in Edwards Lifesciences Corporation $EW

Bath Savings Trust Co trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 21.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,080 shares of the medical research company’s stock after selling 2,455 shares during the quarter. Bath Savings Trust Co’s holdings in Edwards Lifesciences were worth $710,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $266,000. Bank Pictet & Cie Europe AG lifted its position in shares of Edwards Lifesciences by 16.7% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company’s stock valued at $757,000 after acquiring an additional 1,463 shares in the last quarter. Snowden Capital Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $204,000. State of Wyoming lifted its position in Edwards Lifesciences by 128.2% during the fourth quarter. State of Wyoming now owns 1,935 shares of the medical research company’s stock worth $143,000 after buying an additional 1,087 shares during the period. Finally, Tidal Investments LLC lifted its position in Edwards Lifesciences by 18.8% during the fourth quarter. Tidal Investments LLC now owns 46,970 shares of the medical research company’s stock worth $3,477,000 after buying an additional 7,438 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $75.20 on Thursday. The firm has a market capitalization of $44.15 billion, a PE ratio of 10.82, a P/E/G ratio of 3.62 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a 50-day moving average of $78.84 and a two-hundred day moving average of $75.47. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Mizuho increased their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Piper Sandler increased their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Morgan Stanley increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Citigroup reiterated a “buy” rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Finally, Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 13th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $87.17.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.